Inter Parfums earnings, sales fall in 2009
This article was originally published in The Rose Sheet
Executive Summary
Despite a strong fourth quarter, earnings and sales at New York-based fragrance firm Inter Parfums fell for the full year. Earnings slipped 6% to $22.4 mil. and sales declined 8.2% to $409.5 mil. for the year, though the performance was "better than anticipated" considering the global economic downturn and the absence of a major women's fragrance launch, EVP and CFO Russell Greenberg notes in a release. Fourth-quarter sales were up 13% to $112.9 mil. and profit increased 7% to $5.5 mil. Firm plans introduction of Burberry Sport fragrance for men and women in 2010, as well as a Burberry cosmetics collection. New women's scents are slated to roll out from firm's Lanvin and Paul Smith brands, as are new scents for both men and women under the Van Cleef & Arpels label. Launch of first Jimmy Choo fragrance is expected in early 2011
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.